Drug Type AAV based gene therapy |
Synonyms LX 102(Innostellar Biotherapeutics), LX-102(Innostellar Biotherapeutics), LX102(Innostellar Biotherapeutics) + [1] |
Target |
Mechanism VEGF modulators(Vascular endothelial growth factor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet age-related macular degeneration | Phase 2 | CN | 19 Jan 2023 |
Not Applicable | 6 | dhwhraoqef(stxyvilvqg) = Intravitreal injection of LX102-C01 was safe and generally well tolerated during 2 years of follow up. No LX102-C01-related serious adverse events were noted; anterior uveitis was reported in 5 subjects, and were all generally mild and resolved with topical corticosteroid. No evidence of vasculitis, retinitis, choroiditis, vascular occlusions or endophthalmitis was reported. qodzbgggsa (ixfyoxejux ) View more | Positive | 19 Sep 2024 |